Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of transmembrane activator and calcium-modulating cyclophilin ligand interactor and fragment crystallizable portion of immunoglobulin G (IgG), which neutralizes the B lymphocyte stimulator and a proliferation-inducing ligand. Methods This phase 2 randomized placebo-controlled trial aimed to evaluate the efficacy and safety of telitacicept in patients with IgAN. Participants with an estimated glomerular filtration rate (eGFR) >35 ml/min per 1.73 m 2 and proteinuria ≥0.75 g/d despite optimal supportive therapy, were randomized 1:1:1 to receive subcutaneous telitacicept 160 mg, telitacicept 240 mg, or placebo weekly for 24 weeks. The primary end point was the change in 24-hour proteinuria at week 24 from baseline. Results Forty-four participants were randomized into placebo ( n = 14), telitacicept 160 mg ( n = 16), and telitacicept 240 mg ( n = 14) groups. Continuous reductions in serum IgA, IgG, and IgM levels were observed in the telitacicept group. Telitacicept 240 mg therapy reduced mean proteinuria by 49% from baseline (change in proteinuria vs. placebo, 0.88; 95% confidence interval, −1.57 to −0.20; P = 0.013), whereas telitacicept 160 mg reduced it by 25% (−0.29; 95% confidence interval, −0.95 to 0.37; P = 0.389). The eGFR remained stable over time. Adverse events (AEs) were similar in all groups. Treatment-emergent AEs were mild or moderate, and no severe AEs were reported. Conclusion Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria
Macpherson, A. J., & Uhr, T. (2004) · Science · doi:10.1126/science.1091334 · Cited by 1,584
Fellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Cited by
IgA nephropathy: Update on pathogenesis and treatment
Ramsawak, S., Cohen, S., Linares, A., & Cavanaugh, C. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24105 · Cited by 23
The expanding role of biomarkers in the management of IgA nephropathy
Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.004 · Cited by 6
“60,61,74 Given the roles of BAFF and APRIL in IgAN pathogenesis and the preliminary clinical data that are currently emerging, they clearly have potential as noninvasive biomarkers for IgAN and could help inform treatment decisions or monitor treatment response for individual patients in the future.”
Metadata
- Authors
- Lv, J., Liu, L., Hao, C., Li, G., Fu, P., Xing, G., Zheng, H., Chen, N., Wang, C., Luo, P., Xie, D., Zuo, L., Li, R., Mao, Y., Dong, S., Zhang, P., Zheng, H., Wang, Y., Qin, W., Wang, W., Li, L., Jiao, W., Fang, J., & Zhang, H.
- Venue
- Kidney International Reports
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 8
- Issue
- 3
- Pages
- 499-506
- ISSN
- 2468-0249 (ISSN-L)
- OpenAlex
- W4313334095
- Cited by
- 197
- References
- 2
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. https://app.cochat.ai/papers/10.1016/j.ekir.2022.12.014
- The paper
- Lv, J., Liu, L., Hao, C., Li, G., Fu, P., Xing, G., Zheng, H., Chen, N., Wang, C., Luo, P., Xie, D., Zuo, L., Li, R., Mao, Y., Dong, S., Zhang, P., Zheng, H., Wang, Y., Qin, W., . . . Zhang, H. (2023). Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney International Reports. https://doi.org/10.1016/j.ekir.2022.12.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.